



STAFF REPORT

Breast Cancer Diagnostic and Drug Technologies: *Global Markets*

June 2018

BCC Research Staff

Report Code: HLC106C

Table of Contents

Chapter 1: Introduction	2
Study Goals and Objectives.....	2
Reasons for Doing This Study.....	2
Scope of Report.....	3
Information Sources.....	3
Methodology.....	4
Geographic Breakdown.....	5
Analyst's Credentials.....	9
Related BCC Research Reports.....	9
Chapter 2: Summary and Highlights	11
Chapter 3: Market and Technology Background	14
Introduction	14
Classification of Breast Cancer by Type	16
Molecular Subtypes of Breast Cancer	27
Causes, Indications and Risk Factors	31
Symptoms.....	31
Breast Cancer Staging.....	32
Epidemiology.....	33
Chapter 4: Breast Cancer Market Dynamics	43
Market Drivers	43
Increasing Incidence of Breast Cancer Worldwide.....	43
Focused Research and Development for Novel Drugs.....	44
High Increase in Healthcare Expenditure and Funding	46
Increasing Breast Cancer Screening Programs	47
Favorable Reimbursement for Screening and Diagnosis	47
Market Restraints	48
Pricing Pressure Experienced by Innovators	48
High Cost Associated with New Drug Development and Clinical Trials	48
Regulatory and Reimbursement Hurdles	48
Market Opportunity.....	49
Rising Female Population in Asia Pacific	49
Increased Demand for Technology Innovation	49
Technological Advancement in the Drug Sector	50
Emergence of Breast Cancer Predictive Tests.....	50
Opportunity for Generic Manufacturers to Exploit Patents at the Verge of Expiry.....	51
Breast Cancer Therapy: Unmet Needs	53
Chapter 5: Market Breakdown by Technology	55
Breast Cancer Diagnostic Market.....	55
Mammography	55
Latest Developments.....	56
Mammography Procedure Volumes	56
Global Mammography Market.....	59
Limitations of Mammography.....	62
Breast Biopsy Device Market	63

Introduction.....	63
Global Breast Biopsy Device Market	63
Breast Cancer Predictive Diagnostic Market	64
Introduction.....	64
Predictive Diagnostic Tests.....	65
Global Breast Cancer Companion Diagnostic Test Market	66
Chapter 6: Market Breakdown by Drug Class.....	69
Overview	69
Breast Cancers Drug Classes	69
Breast Cancer Market	70
Antimetabolites.....	71
Tanaxanes.....	71
Aromatase Inhibitors.....	72
HER2 Inhibitor	73
Hormone Therapy	75
Chapter 7: Market Breakdown by Region	78
Breast Cancer Incidence by Region.....	78
Global Market by Region	78
North America	79
Europe	81
Asia-Pacific.....	83
Middle East and Africa (MEA)	84
South America	85
Chapter 8: Regulatory Scenario.....	88
Breast Cancer Diagnostics and Therapeutics Regulatory Challenges.....	88
North America.....	88
Food and Drug Administration (FDA)	88
Europe.....	94
Asia-Pacific	97
Japan.....	97
China	98
South America.....	98
Brazil	98
Chapter 9: Patent Review/New Developments	100
Patent Review	100
Companion Diagnostics.....	101
Patent Expiration.....	102
Chapter 10: Reimbursement Landscape	105
Introduction	105
United States.....	105
Mammography Procedure Reimbursement	105
Biopsy Procedure Reimbursement.....	106
Breast Cancer Drugs Reimbursement	108
Germany.....	109
Mammography Procedure Reimbursement	109
Biopsy Procedure Reimbursement.....	112
Breast Cancer Drugs Reimbursement	114

Mexico.....	115
Brazil.....	115
Chapter 11: Pipeline Analysis	118
Introduction	118
Breast Cancer Therapeutics Pipeline by Phases	119
Phase III	119
Phase II	121
Phase I	123
Breast Cancer Therapeutics Pipeline by Company	124
AbbVie, Inc.	124
Array BioPharma, Inc.....	124
AstraZeneca.....	126
Belrose Pharmaceuticals	127
Beta Pharma	127
BioMarin Pharmaceuticals	128
CASI Pharmaceuticals, Inc.	128
Celgene.....	129
Celldex Therapeutics	130
Celsion	131
Clovis	131
Eli Lilly.....	132
Novartis	132
Pfizer.....	133
Puma Biotechnology.....	133
Roche.....	134
Syndax Pharmaceuticals.....	135
Tesaro Inc.	136
Chapter 12: Competitive Landscape	138
Major Mammography Equipment Market Players.....	138
Major Breast Cancer Drug Market Players	139
Chapter 13: Company Profiles	143
Appendix: Abbreviations.....	176
About BCC Research	178
About BCC Research.....	179
BCC Membership	179
BCC Custom Research	179

List of Tables

Summary Table: Global Breast Cancer Diagnostic and Drug Market, by Technology, Through 2022 (\$ Millions)	11
Table 1 Difference between Normal and Benign Breast Cancer Cells.....	15
Table 2 New Female Breast Cancer Cases and Deaths in the United States, by Age, 2017 (No./%).....	18
Table 3 Histological Types, Frequency of Occurrence and Rate of Survival (%).....	22
Table 4 Different Mucinous Carcinoma	24
Table 5 Critical Steps and Genes Involved in Breast Cancer Metastasis.....	26
Table 6 Characteristics of Molecular Subtypes of Invasive Breast Cancer	28
Table 7 Local-Regional Recurrence, by Molecular Subtype (%).....	29
Table 8 Local-Regional Recurrence, by Molecular Subtypes	31
Table 9 Local-Regional Recurrence, by Molecular Subtype.....	32
Table 10 Global Breast Cancer Incidence, 2016-2021 (Thousands).....	34
Table 11 Global Breast Cancer Incidence and Mortality, 2008 (Thousands).....	36
Table 12 New Breast Cancer Cases, by Region, 2009 and 2012 (No.)	38
Table 13 New Breast Cancer Cases in the United States, by Gender, 2010-2019	39
Table 14 New Female Breast Cancer Cases and Deaths in the United States, by Age, 2011 (No.)	39
Table 15 Breast Cancer Incidence and Mortality in the United States, 2011 (No.).....	40
Table 16 Global Breast Cancer Incidence, by Country, Through 2012 (No.)	40
Table 17 Asia-Pacific Breast Cancer Incidence and 40+ Female Population, Through 2017	49
Table 18 List of Breast Cancer Drugs and Their Patent Exclusivity Period.....	51
Table 19 Femara Revenue, 2009-2015	52
Table 20 Indicative List of Available Generic Versions of Letrozole.....	52
Table 21 Global Mammography Market, by Region, Through 2022 (\$ Millions)	61
Table 22 Global Mammography Market, by Device Type, Through 2022 (\$ Millions)	61
Table 23 Global Breast Cancer Biopsy Device Market, by Region, Through 2022 (\$ Millions).....	63
Table 24 Indicative List of Available Breast Cancer Prognostic, Diagnostic, Monitoring and Grading Diagnostics Tests, 2017.....	65
Table 25 Different Classes of Breast Cancer Drugs.....	69
Table 26 Global Breast Cancer Drugs Market, by Drug Class, Through 2022 (\$ Millions).....	70
Table 27 Global Aromatase Inhibitor Drugs Market, by Drug Type, Through 2022 (\$ Millions)	72
Table 28 Global HER2 Inhibitor Drugs Market, by Drug Type, Through 2022 (\$ Millions)	74
Table 29 Global Hormone Receptor Drugs Market, by Drug Type, Through 2022 (\$ Millions).....	76
Table 30 Global Breast Cancer Therapy Market, by Region, Through 2022 (\$ Millions).....	79
Table 31 North America Breast Cancer Therapy Market, by Country, Through 2022 (\$ Millions).....	81
Table 32 European Breast Cancer Therapy Market, by Country, Through 2022 (\$ Millions).....	81
Table 33 Breast Cancer Incidence, Men and Women (Germany in Number of Persons)	82
Table 34 Asia-Pacific Breast Cancer Therapy Market, by Country, Through 2022 (\$ Millions)	83
Table 35 List of FDA-Approved Drugs, 1996-2017	90
Table 36 List of FDA-approved Companion Diagnostics, 2018.....	91
Table 37 List of Breast Cancer Drugs Approved by the EMA, 1995-2018.....	94
Table 38 Companion Diagnostics Patent Review, 2015-2017	101
Table 39 Breast Cancer Therapeutics Patent Review, 2010-2018.....	101
Table 40 Patent Expiration of Breast Cancer Drugs.....	102
Table 41 United States Mammography Reimbursement, 2017	106
Table 42 United States Biopsy Procedure Reimbursement, 2017	106
Table 43 Medicare Part B: Breast Cancer Drugs Payment Limit, 2018.....	109
Table 44 Mammography In-Patient Procedure Reimbursement	110

Table 45 In-Patient Biopsy Procedure Codes.....	112
Table 46 Breast Cancer Drugs Gemzar and Herceptin Reimbursement, Germany, 2017	115
Table 47 Indicative List of Phase III Breast Cancer Therapy Pipeline.....	119
Table 48 Indicative List of Phase II Breast Cancer Therapy Pipeline.....	121
Table 49 Indicative List of Phase I Breast Cancer Therapy Pipeline.....	123
Table 50 AbbVie, Inc.: Pipeline Drugs	124
Table 51 Array BioPharma, Inc.: Pipeline Drugs	125
Table 52 AstraZeneca: Pipeline Drugs.....	126
Table 53 Belrose Pharmaceuticals: Pipeline Drugs.....	127
Table 54 Beta Pharma: Pipeline Drugs.....	127
Table 55 BioMarin Pharmaceuticals: Pipeline Drugs	128
Table 56 CASI Pharmaceuticals, Inc.: Pipeline Drugs	128
Table 57 Celgene: Pipeline Drugs.....	129
Table 58 Celldex Therapeutics: Pipeline Drugs.....	130
Table 59 Celsion: Pipeline Drugs.....	131
Table 60 Clovis: Pipeline Drugs	131
Table 61 Eli Lilly: Pipeline Drugs.....	132
Table 62 Novartis: Pipeline Drugs	132
Table 63 Pfizer, Inc.: Pipeline Drugs.....	133
Table 64 Puma Biotechnology: Pipeline Drugs	134
Table 65 Roche: Pipeline Drugs.....	134
Table 66 Syndax Pharmaceuticals: Pipeline Drugs.....	136
Table 67 Tesaro, Inc.: Pipeline Drugs.....	136
Table 68 AbbVie, Inc.: Company Net Revenue, 2014-2017 (\$ Billions)	144
Table 69 Abbott Laboratories: Company Net Revenue, 2014-2017 (\$ Billions).....	147
Table 70 Abbott Laboratories: Marketed Products, 2016	148
Table 71 AstraZeneca Plc.: Company Net Revenue, 2014-2017 (\$ Billions)	149
Table 72 AstraZeneca Plc.: Revenue, by Segment, Through 2016 (\$ Millions).....	149
Table 73 AstraZeneca Plc.: Marketed Products, 2016	151
Table 74 Bristol-Myers Squibb Company: Net Revenue, 2014-2016 (\$ Millions).....	154
Table 75 Eli Lilly and Company: Net Revenue, 2014-2017 (\$ Billions).....	158
Table 76 Eli Lilly and Company: Net Revenue, by Segment, 2014-2016 (\$ Millions)	159
Table 77 Eli Lilly and Company: Revenue, by Oncology Drugs, 2014-2016 (\$ Millions)	159
Table 78 F. Hoffmann-La Roche, Ltd.: Net Revenue, by Segment, Through 2017 (\$ Millions).....	161
Table 79 Novartis International AG: Net Revenue, by Segment, Through 2017 (\$ Millions)	166
Table 80 Pfizer, Inc.: Net Revenue, 2014-2016 (\$ Millions).....	168
Table 81 Pfizer, Inc.: Oncology Drugs Revenue, 2015-2016 (\$ Millions)	168
Table 82 Abbreviations Used in Breast Cancer Diagnostic and Drug Technology	176

List of Figures

Summary Figure: Global Breast Cancer Diagnostic and Drug Market, by Technology, 2016-2022 (\$ Millions)	12
Figure 1 Breast Anatomy of Normal and Cancerous Ducts and Lobules	15
Figure 2 Market Share of Invasive and Non-invasive Breast Cancer, United States, 2017 (%)	17
Figure 3 Histopathological Classification of Breast Cancer	18
Figure 4 Non-invasive Breast Cancer Cases in the United States, 2015 (Number of Cases)	19
Figure 5 New Cases of Invasive Breast Cancer in the United States, 2015 (Number of Cases).....	21
Figure 6 Invasive Breast Cancers Market Share, by Type (%)	23
Figure 7 Occurrence of Molecular Subtypes (%).....	27
Figure 8 Global Burden of Breast Cancer	35
Figure 9 National Cancer Institute Research Funding, 2011-2016 (\$ Millions)	45
Figure 10 NCRI Breast Cancer Research Spending, 2010-2017 (\$ Millions*)	46
Figure 11 Total Number of Mammography Procedures in the United States, Canada and Mexico, 2010-2015 (Per 1,000,000 Inhabitants)	57
Figure 12 Total Number of Mammography Procedures in Europe, 2010-2015 (Per 1,000,000 Inhabitants)	58
Figure 13 Total Number of Mammography Procedures in Asia-Pacific, 2010-2015 (Per 1,000,000 Inhabitants).....	59
Figure 14 Global Mammography Market, 2016-2022 (\$ Millions)	60
Figure 15 Global Breast Cancer Companion Diagnostic Market, 2016-2022 (\$ Millions)	67
Figure 16 Global Breast Cancer Drugs Market Share, by Drug Class, 2016 (%)	71
Figure 17 Global Aromatase Inhibitor Drugs Market, by Drug Type, 2016-2022 (\$ Millions)	73
Figure 18 Global HER2 Inhibitor Drugs Market, by Drug Type, 2016-2022 (\$ Millions)	75
Figure 19 Global Hormone Receptor Drugs Market, by Drug Type, 2016-2022 (\$ Millions).....	76
Figure 20 Global Breast Cancer Incidence, by Region, 2012 (Per 100,000 Persons)	78
Figure 21 Middle East and Africa Breast Cancer Therapy Market, by Country, 2016-2022 (\$ Millions) ..	85
Figure 22 South America Breast Cancer Therapy Market, by Country, 2016-2022 (\$ Millions).....	86
Figure 23 Federal and Inter-Provincial Approval System for Cancer Drugs in Canada.....	94
Figure 24 Medical Device PMDA Approval Procedure.....	97
Figure 25 Reimbursement of Drugs in Germany	114
Figure 26 Global Market Share of Mammography Equipment, by Company, 2016* (%)	138
Figure 27 Global Market Share of Breast Cancer Drugs, by Company, 2016 (%)	140
Figure 28 AbbVie, Inc.: Net Revenue, 2013-2016 (\$ Billions)	144
Figure 29 AbbVie, Inc.: Lupron Sales, 2014-2016 (\$ Millions)	145
Figure 30 Abbott Laboratories: Revenue Share, by Segment, 2016 (%).....	147
Figure 31 AstraZeneca Plc.: Revenue, by Drug, 2014-2016 (\$ Millions)	150
Figure 32 Bristol-Myers Squibb Company: Revenue Share, by Region, 2016 (%)	154
Figure 33 Bristol-Myers Squibb Company: Revenue Share, by Business Segment, 2016 (%)	155
Figure 34 Eli Lilly and Company: Revenue Share, by Region, 2016 (%)	160
Figure 35 F. Hoffmann-La Roche, Ltd.: Pharmaceuticals Revenue Share, by Business Segment, 2016 (%)	162
Figure 36 F. Hoffmann-La Roche, Ltd.: Breast Cancer Drugs Revenue, 2014-2017 (\$ Millions).....	163
Figure 37 F. Hoffmann-La Roche, Ltd.: Breast Cancer Drugs Revenue, by Region, 2016 (%)	164
Figure 38 Novartis International AG: Breast Cancer Drugs Revenue, 2014-2016 (\$ Millions)	167
Figure 39 Pfizer, Inc.: Breast Cancer Drugs Revenue, 2015 and 2016 (\$ Millions)	169
Figure 40 Aromasin Revenue, 2010-2013 (\$ Millions).....	169
Figure 41 Sanofi S.A.: Pharmaceuticals Segment Revenue Share, by Therapy, 2017 (%).....	172

Figure 42 Sanofi S.A.: Breast Cancer Drug Taxotere Revenue, 2011-2017 (\$ Millions)..... 173



About BCC Research

About BCC Research

With our unparalleled 45-year history, BCC Research provides comprehensive analysis of global market sizing, forecasting and industry intelligence, covering markets where advances in science and technology are improving the quality, standard and sustainability of businesses, economies and lives.

BCC Membership

From market sizing and forecasts, to opportunity assessments and competitive analyses, our ever-expanding library gives you the data, insights and intelligence required to ensure your project is a success. Members benefit from ongoing, unlimited access to the category or collections of their choice, and most membership packages pay for themselves within two to three reports being accessed.

Did you buy this report? You may qualify to apply your purchase price towards a full membership. Call 866/285-7215 or email info@bccresearch.com to request a demo.

BCC Custom Research

Our experts provide custom research projects to those working to identify new markets, introduce new products, validate existing market share, analyze competition and assess the potential for products to impact existing markets. With impressive academic credentials and broad and deep knowledge of global industrial markets, our independent analysts and consultants develop the facts, figures, analysis and assessments to inform the decisions that will move your company ahead. Confidential inquiries to: custom@bccresearch.com or 781-205-2429.

DISCLAIMER

The information developed in this report is intended to be as reliable as possible at the time of publication and is of a professional nature. This information does not constitute managerial, legal or accounting advice, nor should it be considered as a corporate policy guide, laboratory manual or an endorsement of any product, as much of the information is speculative in nature. BCC Research and the author assume no responsibility for any loss or damage that might result from reliance on the reported information or from its use.

ISBN: 978-1-62296-751-3
June 2018